Silicon-based agent mitigates fatty liver formation in a CDAHFD60-induced MASH mouse model by enhancing hepatic...

Area of Science:

• Hepatology
• Metabolic Disorders
• Oxidative Stress Research

Background:

• Metabolic dysfunction-associated steatohepatitis (MASH) is a growing liver disease linked to obesity and metabolic syndrome.
• MASH progression increases risks for cardiovascular events, cirrhosis, and liver cancer.
• Oxidative stress is a key driver of MASH, necessitating antioxidant-based therapies.

Purpose of the Study:

• To investigate the therapeutic potential of a silicon (Si)-based agent in a mouse model of MASH.
• To evaluate the effects of Si-based agent on hepatic lipid accumulation, bile dysfunction, and systemic metabolism.

Main Methods:

• A choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD60) was used to induce MASH in mice.
• Mice were administered a Si-based agent mixed into their diet for 12 weeks.
• Hepatic lipid accumulation, bile dysfunction, weight changes, and systemic oxidative stress were assessed.

Main Results:

• Si-based agent treatment reduced hepatic lipid droplet accumulation by mitigating bile dysfunction.
• Treatment alleviated hypolipidemia and suppressed weight loss observed in the MASH model.
• The Si-based agent demonstrated systemic antioxidant effects, reducing overall oxidative stress.

Conclusions:

• Silicon (Si)-based agents show therapeutic potential for MASH by improving hepatic and systemic lipid metabolism.
• The antioxidant properties of Si-based agents contribute to their beneficial effects in MASH.
• Further research into Si-based agents could lead to novel treatments for MASH and related metabolic disorders.